Deep Brain Stimulation for Parkinson's Disease

(BOG DBS Trial)

This trial tests a method called deep brain stimulation (DBS) to improve walking problems in people with Parkinson's disease. Researchers aim to determine if a specific technique can fine-tune DBS settings to enhance walking ease and consistency. Participants must have Parkinson’s disease and have undergone DBS surgery at least three months prior. This trial excludes those unable to walk even with assistance or those with significant walking issues from other conditions. As an Early Phase 1 trial, this research seeks to understand how the treatment works in people, offering participants a chance to contribute to groundbreaking advancements in Parkinson's care.

Research has shown that deep brain stimulation (DBS) is generally safe for people with Parkinson's disease. Studies have found that patients often experience significant improvements in movement and balance after receiving DBS. For example, many patients report fewer falls and enhanced physical abilities, indicating that the treatment is well-tolerated.

DBS has been used for a long time to treat Parkinson's, and most patients do not experience serious side effects. Some might notice slight changes in thinking, but these are rare and minor. Long-term studies also support DBS as a safe choice, showing it might even help patients live a bit longer.

Unlike other treatments for Parkinson's Disease, which often include medications like levodopa or dopamine agonists, Deep Brain Stimulation (DBS) offers a surgical option that directly targets brain activity. DBS involves implanting electrodes in specific brain areas to modulate abnormal signals, potentially reducing symptoms like tremors and rigidity more effectively. Researchers are excited about DBS because it provides a more personalized approach, allowing for adjustments in stimulation to meet individual patient needs, and it may also reduce the need for high doses of medication, minimizing side effects.

Studies have shown that deep brain stimulation (DBS) can improve movement problems in people with Parkinson's disease, such as tremors and stiffness. Research indicates that targeting specific brain areas, like the subthalamic nucleus (STN) or globus pallidus (GP), has effectively improved movement control. Early findings suggest that DBS can significantly enhance walking ability in Parkinson's patients. While there is much hope, results can vary, and ongoing research aims to refine the method for better outcomes. In this trial, all participants will receive DBS, and the study explores whether adjusting DBS settings using a method called Bayesian optimization can further improve walking in Parkinson's patients.⁶⁷⁸⁹¹⁰